BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
ADBRY (tralokinumab-ldrm) by Leo Pharma is interleukin-13 antagonists [moa]. Approved for atopic dermatitis. First approved in 2021.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADBRY (tralokinumab-ldrm) is a monoclonal antibody that selectively blocks interleukin-13 (IL-13), a key cytokine in atopic dermatitis pathogenesis. It is indicated for moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or for whom those therapies are not advisable. The drug represents a targeted biologic approach to a disease traditionally managed with topical corticosteroids and calcineurin inhibitors. ADBRY was approved by the FDA on December 27, 2021, and occupies a position in the emerging class of IL-13 antagonists for inflammatory skin diseases.
$0.0BPart D
Mechanism of Action
Interleukin-13 Antagonists
Pharmacologic Class:
Interleukin-13 Antagonist
Indications (1)
Career Relevance
ADBRY's commercial status in peak lifecycle stage creates career opportunities for brand managers, field medical liaisons (MSLs), sales representatives, and medical affairs specialists focused on dermatology and immunology. Success in this role requires deep knowledge of atopic dermatitis pathophysiology, IL-13 biology, payer/formulary landscapes, and the ability to differentiate a premium-priced biologic from lower-cost topical and systemic alternatives. Currently, there are zero open positions linked to this product in the available dataset, suggesting either mature team staffing or limited active hiring at this time.
Worked on ADBRY at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.